CLCA2 Antibody

What is the optimal sample preparation method for CLCA2 antibody detection in Western blot applications?

For effective Western blot detection of CLCA2, researchers should follow these methodological steps:

• Prepare fresh tissue or cell lysates in RIPA buffer containing protease inhibitors

• Load 20-40μg protein per lane after quantification

• Use 8-10% SDS-PAGE gels to accommodate the 104-141 kDa molecular weight of CLCA2

• Transfer to PVDF membranes at 100V for 90 minutes in cold transfer buffer

• Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary CLCA2 antibody at 1:500-1:1000 dilution overnight at 4°C

Note that CLCA2 may appear at both 141 kDa (precursor) and 35-40 kDa (cleaved C-terminal fragment) on immunoblots due to its self-cleavage properties . For mouse samples, lung tissue lysates provide a reliable positive control .

How should researchers optimize immunohistochemistry protocols for CLCA2 detection in tissue samples?

For optimal CLCA2 immunohistochemical detection:

• Fix tissue samples in 10% neutral buffered formalin and embed in paraffin

• Section tissues at 4-5μm thickness

• Perform antigen retrieval using TE buffer (pH 9.0) or alternatively citrate buffer (pH 6.0)

• Block endogenous peroxidase activity with 3% H₂O₂

• Apply primary CLCA2 antibody at 1:20-1:200 dilution depending on tissue type

• Incubate overnight at 4°C

• Detect using HRP-conjugated secondary antibody and DAB chromogen

Human esophagus tissue serves as a reliable positive control for IHC applications. Researchers should always include both positive and negative controls to validate staining specificity and optimize dilution factors in each experimental system .

What are the key considerations when selecting a CLCA2 antibody for experimental applications?

When selecting a CLCA2 antibody, researchers should consider:

• Epitope location: Antibodies targeting different domains may yield different results. The TVE20 antibody (targeting aa643-663) recognizes both precursor and cleaved forms on immunoblots but only immunoprecipitates the precursor form due to conformational changes after cleavage .

• Cross-reactivity: Some CLCA family members share high sequence homology. For example, mouse CLCA3a1 and CLCA3a2 share 92% amino acid identity, requiring careful antibody selection to avoid cross-reactivity .

• Application compatibility: Verify that the antibody has been validated for your specific application:

  • For Western blot: Polyclonal antibodies like 19273-1-AP show reactivity with both human and mouse samples

  • For immunoprecipitation: Select antibodies specifically validated for IP applications

  • For immunohistochemistry: Consider antigen retrieval requirements

• Cleavage awareness: CLCA2 undergoes zinc-dependent autoproteolysis. Select antibodies that can detect your target form (precursor at ~135-141 kDa or cleaved products) .

How can researchers distinguish between CLCA2 expression patterns in different cancer subtypes for diagnostic purposes?

CLCA2 has emerged as a valuable biomarker for distinguishing between squamous cell carcinoma (SCC) and adenocarcinoma (ADC) of the lung, with significant diagnostic implications:

• Immunohistochemical scoring protocol:

  • Calculate immunohistochemical scores based on staining intensity (0-3) multiplied by percentage of positive cells

  • Use a cutoff value of 100 for defining positive CLCA2 expression (score > 100)

• Expected expression patterns:

  • SCC: 64.6% positivity rate with cytoplasmic and membranous staining

  • ADC: Only 0.9% positivity rate

• Diagnostic accuracy:

  Parameter	Value
  Sensitivity	64.6%
  Specificity	99.1%

• Association with histological grading:

  Grading	CLCA2 Positive	CLCA2 Negative
  G1 or G2	86 (74.8%)	29 (25.2%)
  G3	18 (39.1%)	28 (60.9%)

This approach demonstrates that CLCA2 is a highly specific marker for SCC with a significant association with tumor differentiation grade (p<0.0001) .

What methodological approaches can resolve the contradictory findings between CLCA2's tumor suppressive role in some cancers versus its potential oncogenic properties in others?

To address contradictory findings regarding CLCA2's role in cancer progression:

• Implement tissue-specific expression profiling:

  • Compare CLCA2 expression between matched tumor and adjacent normal tissues

  • In cervical cancer studies, RT-qPCR revealed decreased CLCA2 expression in tumor tissues compared to adjacent normal tissues

• Correlate with clinicopathological parameters:

  • Analyze CLCA2 expression with respect to:

    • Tumor stage (p=0.028)

    • Tumor size (p=0.009)

    • HPV infection status (p=0.041)

• Conduct functional validation experiments:

  • Knockdown studies: siRNA-mediated CLCA2 suppression promotes cancer cell proliferation and migration

  • Overexpression studies: Ectopic CLCA2 expression inhibits cancer cell migration and increases cell adhesiveness

• Investigate signaling pathway interactions:

  • CLCA2 knockdown leads to increased expression of FAK (focal adhesion kinase)

  • CLCA2 appears to regulate the Wnt/β-catenin signaling pathway in cervical cancer

These methodological approaches suggest that CLCA2's function is context-dependent, acting as a tumor suppressor in cervical cancer by inhibiting cell proliferation, migration, and invasion through modulation of specific signaling pathways.

How should researchers design experiments to investigate the relationship between CLCA2's metalloprotease activity and its regulation of store-operated calcium entry (SOCE)?

To investigate the functional relationship between CLCA2's metalloprotease activity and SOCE regulation:

• Generate and validate metalloprotease-deficient mutants:

  • Create E165Q point mutation in the HEXXH zinc-binding motif

  • Confirm loss of cleavage activity via immunoblotting of cell lysates and membrane preparations

• Develop co-expression systems for trans-cleavage studies:

  • Co-transfect differentially tagged CLCA2 constructs (e.g., CLCA2-Flag and CLCA2-Myc)

  • Perform co-immunoprecipitation to confirm protein-protein interactions

  • Quantify cleavage efficiency under varying expression conditions

• Establish calcium imaging protocols:

  • Use Fura-2 ratiometric method to measure cytosolic calcium levels

  • Compare:
    a) ER calcium release in response to thapsigargin
    b) SOCE after store depletion in:

    • Vector control cells

    • Wildtype CLCA2-expressing cells

    • E165Q mutant-expressing cells

• Investigate protein-protein interactions with SOCE components:

  • Perform co-immunoprecipitation between CLCA2 and SOCE mediators (STIM1 and Orai1)

  • Quantify interaction efficiency:

    • Anti-Flag antibody pulled down 9% of total ORAI-1 from CLCA2-expressing cells

    • Anti-ORAI1 pulled down 11% of total CLCA2

This experimental design has revealed that the E165Q mutation abolishes both CLCA2 cleavage and SOCE stimulation, establishing that metalloprotease activity is required for CLCA2's regulatory function in calcium signaling .

What immunoprecipitation strategies can overcome the conformational challenges associated with cleaved CLCA2 detection?

The conformational shift in CLCA2 following cleavage presents a significant challenge for immunodetection. Researchers can implement these specialized immunoprecipitation protocols:

These methods have revealed that CLCA2 cleavage induces a significant conformational shift that affects epitope accessibility, providing critical insights into the structure-function relationship of this protein.

What are the best approaches to resolve inconsistent CLCA2 antibody staining patterns in tissue microarrays?

Inconsistent CLCA2 staining patterns in tissue microarrays (TMAs) can be resolved through:

• Standardized tissue processing:

  • Ensure consistent fixation time (24 hours in 10% neutral buffered formalin)

  • Implement standardized antigen retrieval methods (TE buffer pH 9.0 is recommended for CLCA2)

• Antibody validation steps:

  • Perform antibody titration (1:20, 1:50, 1:100, 1:200) on control tissues

  • Include known positive controls (human esophagus tissue for CLCA2)

  • Run parallel negative controls (primary antibody omission and isotype controls)

• Scoring system optimization:

  • Implement a semi-quantitative immunohistochemical scoring system:

    • Staining intensity (0-3) × percentage of positive cells (0-100%)

    • Define clear cutoff values (score > 100 for positivity)

• Multiple observer validation:

  • Have at least two independent pathologists score the TMAs

  • Calculate inter-observer agreement coefficient

  • Resolve discrepancies through consensus review

This standardized approach was successfully implemented in a study of 396 lung cancer specimens, achieving reliable discrimination between squamous cell carcinoma and adenocarcinoma with 99.1% specificity .

How can researchers accurately distinguish between specific CLCA2 signals and non-specific binding in immunofluorescence applications?

To distinguish between specific CLCA2 signals and non-specific binding in immunofluorescence:

• Implement rigorous controls:

  • Positive controls: HEK293 cells stably transduced with CLCA2-Flag

  • Negative controls:

    • Primary antibody omission

    • Use of E165Q mutant CLCA2 for specific epitope confirmation

    • Non-transfected parental cells

• Optimize immunostaining protocol:

  • Fix cells with cold methanol (-20°C for 10 minutes)

  • Block with 1% FBS, 1% BSA in PBS overnight at 4°C

  • Incubate with primary antibodies for 4 hours (anti-STIM-1 at 1:100, anti-Flag at 1:1000)

  • Use fluorophore-conjugated secondary antibodies (AlexaFluor 568 or 488)

• Employ confocal microscopy techniques:

  • Collect Z-stack images using 1μm step size

  • Analyze optical cross-sections to confirm genuine co-localization

  • Use Leica LAS AF Lite software for image acquisition and analysis

• Validate with co-localization studies:

  • Co-stain for known interacting partners (STIM-1, ORAI-1)

  • Quantify co-localization coefficients

  • Confirm with biochemical approaches (co-immunoprecipitation)

This approach has successfully demonstrated genuine co-localization of CLCA2 with STIM-1 at the plasma membrane, confirming their functional interaction in SOCE regulation .

What strategies can resolve the discrepancy between CLCA2 mRNA and protein expression levels observed in some experimental systems?

To address discrepancies between CLCA2 mRNA and protein expression:

• Employ multiple detection methods:

  • Compare RT-qPCR data with immunoblotting results

  • Validate with immunohistochemistry in tissue samples

  • Use RNA-seq data for comprehensive transcriptome analysis

• Investigate post-transcriptional regulation:

  • Assess microRNA targeting of CLCA2 mRNA

  • Measure mRNA stability through actinomycin D chase experiments

  • Analyze polysome profiles to evaluate translational efficiency

• Examine post-translational modifications:

  • Study CLCA2 glycosylation status (heavily glycosylated N-terminal ectodomain)

  • Investigate proteolytic processing (zinc-dependent self-cleavage)

  • Assess protein stability through cycloheximide chase assays

• Analyze epigenetic regulation:

  • Evaluate DNA methylation status of the CLCA2 promoter

  • Study histone modifications at the CLCA2 locus

  • Test the effects of epigenetic modifiers (HDAC inhibitors, DNA methyltransferase inhibitors)

The Cancer Genome Atlas (TCGA) database analysis of 980 lung cancer cases revealed significant differences in CLCA2 mRNA expression between squamous cell carcinoma and adenocarcinoma (median expression value 4,860.0234 versus 5.2242), which correlated with protein expression patterns observed by immunohistochemistry .

How should researchers design experiments to investigate CLCA2's role in regulating store-operated calcium entry in primary cell cultures versus established cell lines?

For investigating CLCA2's role in SOCE across different experimental systems:

• Cell system selection and validation:

  • Primary cells: Isolate bronchial epithelial cells, mammary epithelial cells, or keratinocytes

  • Established lines: HEK293 cells (no endogenous CLCA2) serve as an excellent model system

  • Confirm endogenous CLCA2 expression levels by RT-qPCR and immunoblotting

• Expression manipulation strategies:

  • Primary cells: Use lentiviral transduction for stable expression or siRNA for knockdown

  • Cell lines: Generate stable cell lines through antibiotic selection (puromycin at 1 μg/mL)

  • Verify expression by immunoblotting with anti-CLCA2 or epitope tag antibodies

• Calcium measurement protocols:

  • Fura-2 ratiometric method for quantitative measurement:

    • Load cells with Fura-2/AM (2-5 μM) for 30 minutes at room temperature

    • Measure fluorescence ratio (340/380 nm excitation) as indicator of [Ca²⁺]ᵢ

    • Record baseline, ER Ca²⁺ release (with thapsigargin), and SOCE response

• Mechanistic dissection:

  • Compare responses between:

    • Vector control cells

    • CLCA2 wildtype-expressing cells

    • E165Q mutant-expressing cells (lacking metalloprotease activity)

  • Analyze both calcium release from ER stores and subsequent SOCE

This experimental design revealed that the E165Q mutant had substantially less SOCE even than vector control, suggesting a dominant-negative effect and establishing the requirement of metalloprotease activity for CLCA2's function in calcium regulation .

What analytical methods should be used to investigate the intricate relationship between CLCA2 expression, cleavage efficiency, and cancer progression markers?

To investigate the relationship between CLCA2 processing and cancer progression:

• Integrated multi-parameter analysis:

  • Measure CLCA2 expression, cleavage efficiency, and EMT markers in the same samples

  • Correlate with clinicopathological parameters

  • The Cancer Genome Atlas (TCGA) data showed that low CLCA2 expression correlates with higher E-cadherin (p=0.0039), Snail (p=0.0018), and Twist (p=0.0015) expression in lung SCC

• Quantitative assessment of cleavage efficiency:

  • Calculate cleavage ratio: cleaved product / (precursor + cleaved product)

  • Compare across:

    • Tumor grades (G1-G3)

    • Tumor stages

    • Metastatic status

• Pathway analysis techniques:

  • Investigate Wnt/β-catenin signaling in CLCA2-manipulated cells

  • Examine focal adhesion kinase (FAK) activation status

  • Assess epithelial-mesenchymal transition (EMT) marker expression

• Functional assays with cleavage mutants:

  • Compare E165Q mutant with wildtype CLCA2 in:

    • Cell proliferation assays

    • Wound healing migration assays

    • Invasion assays through Matrigel

    • Cell adhesion assays

This integrated approach has revealed that CLCA2 expression is associated with tumor grade in SCC of the lung, and its loss correlates with EMT marker expression, suggesting a mechanistic link between CLCA2 processing and cancer progression .

How can researchers effectively differentiate between CLCA family members when studying their functions in tissues with multiple CLCA protein expression?

Differentiating between CLCA family members in complex tissues requires:

• RNA-level discrimination strategies:

  • Design highly specific RT-qPCR primers targeting unique sequences

  • Perform RNA-seq analysis followed by isoform-specific alignment

  • Use RNA in situ hybridization with isoform-specific probes

• Protein-level discrimination approaches:

  • Select epitope-specific antibodies targeting non-conserved regions

  • Validate antibody specificity using knockout/knockdown controls

  • Be aware that some family members share high sequence identity (e.g., mouse CLCA3a1 and CLCA3a2 share 92% amino acid identity)

• Functional differentiation methods:

  • Compare subcellular localization patterns:

    • CLCA1: fully secreted protein

    • CLCA2: integral membrane protein with a transmembrane segment

  • Assess self-cleavage dependencies:

    • CLCA1: self-cleaves in absence of membranes

    • CLCA2: requires membrane association for efficient cleavage

• Knockout/knockdown validation:

  • Generate isoform-specific knockout models

  • Perform selective knockdown with validated siRNAs

  • Rescue experiments with ectopic expression of specific isoforms

These approaches have successfully distinguished the functions of CLCA1 and CLCA2, revealing that while both enhance calcium-activated chloride channel activity, they do so through different mechanisms: CLCA1 directly interacts with TMEM16A, while CLCA2 regulates store-operated calcium entry through STIM1/Orai1 interaction .

What novel biochemical approaches can elucidate the structural changes in CLCA2 following self-cleavage?

To investigate structural changes in CLCA2 after self-cleavage:

• Epitope accessibility profiling:

  • The TVE20 antibody (targeting aa643-663) detects both precursor and cleaved forms on immunoblots but only immunoprecipitates the precursor

  • Denaturation-renaturation treatment restores epitope recognition in the cleaved form

  • This suggests significant conformational changes upon cleavage

• High-resolution structural analysis techniques:

  • Cryo-electron microscopy of purified CLCA2 before and after cleavage

  • X-ray crystallography of individual domains

  • Hydrogen-deuterium exchange mass spectrometry to map surface accessibility changes

• Oligomerization assessment methods:

  • Analytical ultracentrifugation

  • Size-exclusion chromatography with multi-angle light scattering

  • Chemical crosslinking followed by mass spectrometry

  • Similar approaches with CLCA1 have revealed assembly into high-molecular-weight oligomers consistent with octamers

• Functional domain mapping:

  • Generate and characterize truncation mutants

  • Perform site-directed mutagenesis of key residues

  • Assess protein-protein interactions before and after cleavage